DSO Deutsche Stiftung Organtransplantation

Organspende in Deutschland: Leichter Anstieg, weiterhin großer Bedarf

22. DSO-Jahreskongress: Rund 800 Fachleute diskutieren Herausforderungen und Perspektiven der Organspende

Frankfurt am Main (ots)

In Deutschland ist die Zahl der Organspenden in den ersten neun Monaten des Jahres leicht gestiegen. Zum Auftakt des 22. Jahreskongresses stellte die Deutsche Stiftung Organtransplantation (DSO) die aktuellen Zahlen vor: Von Januar bis September 2026 wurden bundesweit 772 postmortale Organspenderinnen und Organspender verzeichnet. Das sind 28 beziehungsweise 3,8 Prozent mehr als im Vorjahreszeitraum.

Die Zahl der in Deutschland entnommenen Organe, die über die internationale Vermittlungsstelle Eurotransplant vermittelt und anschließend in Deutschland oder im Ausland transplantiert wurden, lag bei 2.373. Im Vorjahreszeitraum waren es 2.258 Organe.

Dr. med. Axel Rahmel, Medizinischer Vorstand der DSO, ordnete die Entwicklung bei der Pressekonferenz zum Kongressauftakt ein: "Der positive Trend aus dem vergangenen Jahr setzt sich erfreulicherweise fort. Dennoch bleibt die Zahl der Organspenden deutlich hinter dem zurück, was notwendig wäre, um den rund 8.000 Menschen, die in Deutschland auf ein Spenderorgan warten, zu helfen. Unser Ziel muss es sein, möglichst vielen von ihnen diese Chance zu eröffnen."

Ein wesentlicher Grund für die weiterhin niedrigen Organspendezahlen ist nach Einschätzung Rahmels, dass häufig keine dokumentierte Entscheidung der potenziellen Spenderinnen und Spender vorliegt. Obwohl die große Mehrheit der Menschen in Deutschland der Organspende positiv gegenübersteht, ist diese Haltung jedoch oftmals nicht schriftlich festgehalten. So bleibt im Ernstfall häufig offen, ob eine Organspende dem Willen des Verstorbenen entsprochen hätte. Die damit verbundene Unsicherheit führt oft dazu, dass Angehörige einer Organspende nicht zustimmen."

Vor diesem Hintergrund begrüßte der DSO-Vorstand die erneute politische Diskussion um die Widerspruchsregelung als wichtiges Signal: "Diese Regelung fördert die persönliche Auseinandersetzung mit dem Thema und wird dazu beitragen, die breite Zustimmung zur Organspende in der Bevölkerung künftig besser abzubilden. Gleichzeitig schafft die Regelung Klarheit und entlastet Angehörige, die im Ernstfall nicht stellvertretend entscheiden müssen. Die Widerspruchsregelung wäre ein wichtiger Baustein zur Förderung der Organspende in Deutschland, zugleich ist sie ein Signal der Hoffnung für die Patientinnen und Patienten auf den Wartelisten."

Medizinische und technische Entwicklungen können ebenfalls dazu beitragen, die Chancen auf eine erfolgreiche Transplantation zu verbessern. Thomas Biet, Kaufmännischer Vorstand der DSO, verwies in diesem Zusammenhang auf die Anfang des Jahres eingeführte Maschinenperfusion für Spendernieren. Seit ihrer Einführung wurde das Verfahren bei über 500 Nieren erfolgreich eingesetzt. "Wir nutzen die technischen Möglichkeiten konsequent und entwickeln unsere Verfahren kontinuierlich weiter. Unser Ziel ist es, Spenderorgane bestmöglich für die Transplantation vorzubereiten", betonte Biet.

Dr. Gerald Gaß, Vorstandsvorsitzender der Deutschen Krankenhausgesellschaft, nahm ebenfalls an der Pressekonferenz teil und hielt im Anschluss die Keynote zur Eröffnung des DSO-Jahreskongresses. Er erklärte: "Organspende ist ein besonderer Ausdruck gesellschaftlicher Solidarität. Damit möglichst viele schwer kranke Menschen von den Möglichkeiten der Transplantationsmedizin profitieren können, brauchen wir neben dem Vertrauen und der selbstbestimmten Entscheidung der Menschen vor allem Krankenhäuser, die personell, organisatorisch und finanziell in der Lage sind, diese verantwortungsvolle Aufgabe zu erfüllen."

"Seine Entscheidung gab uns Sicherheit", sagte Helene Grass bei der Pressekonferenz. Die Film- und Theaterschauspielerin nahm als Angehörige eines Organspenders teil und berichtete vom Tod ihres Ehemanns, des Dirigenten Lutz Rademacher, der im November vergangenen Jahres im Alter von 56 Jahren nach einem plötzlichen Herzstillstand gestorben war. Er konnte zwar reanimiert werden, doch die Folgen waren schwerwiegend. "Der Arzt, der mir sagte, dass es keine Hirntätigkeit mehr gäbe, hat schon gefragt: 'Sie können sich vorstellen, was ich Sie jetzt fragen werde' und daraufhin öffnete ich als Antwort Lutz Portemonnaie und holte den Spenderausweis hervor."

Lutz Rademacher hatte seine Haltung zur Organspende klar dokumentiert. Das gab seiner Familie in einer schwierigen Situation Sicherheit. "Der Gedanke, dass Lutz anderen Menschen Hoffnung schenken konnte, ist und bleibt ein Trost für uns. Dies hat uns in diesen unfassbar schrecklichen Stunden als Familie geholfen", schilderte Helene Grass.

Die Geschichte von Helene Grass zeigt, wie wichtig Klarheit und Verlässlichkeit im entscheidenden Moment sein können. Doch damit aus einer dokumentierten Entscheidung tatsächlich eine Organspende werden kann, braucht es im Krankenhaus viele weitere Voraussetzungen: medizinische Expertise, eingespielte Abläufe, qualifizierte Ansprechpartner und eine gute Zusammenarbeit aller beteiligten Berufsgruppen.

Der 22. Jahreskongress der DSO bringt Fachleute aus der Organspende und Transplantationsmedizin zusammen, um aktuelle Entwicklungen zu diskutieren, Erfahrungen aus der Praxis auszutauschen und die fachliche Zusammenarbeit zu stärken. Rund 800 Teilnehmende verfolgen das Programm in diesem Jahr vor Ort in Frankfurt am Main oder per Livestream.

Auch der medizinische und technische Fortschritt in der Transplantationsmedizin ist wichtiger Teil des Programms. Die Beiträge reichen von den Potenzialen medizinischer Register wie dem Transplantationsregister und KI-basierten Prognosen über erste Erfahrungen mit der Maschinenperfusion in Deutschland bis hin zu neuen Verfahren zur Konservierung von Spenderherzen. Ein simulationsbasierter Praxiskurs sowie ein VR-gestütztes Training, beides zur Diagnostik des irreversiblen Hirnfunktionsausfalls (IHA), ergänzen das Programm.

Eine Premiere ist die erste Live-Aufzeichnung des neuen DSO-Podcast "7 Leben". Das Format richtet sich insbesondere an medizinisches Fachpersonal und behandelt medizinische Fragestellungen sowie praktische Herausforderungen rund um die Organspende. In der ersten Folge geht es um die Begleitung von Angehörigen bei der Diagnostik des irreversiblen Hirnfunktionsausfalls (IHA).

Pressekontakt:

Annika Hollmann, Bereichsleiterin Kommunikation,

mobil: +49 170 2702982

Nadine Körner, Dr. Susanne Venhaus, Presse- und Öffentlichkeitsarbeit

Deutsche Stiftung Organtransplantation

Deutschherrnufer 52, 60594 Frankfurt am Main

Tel.: +49 69 677 328 9400, -9411, -9413, Fax: +49 69 677 328 9409

E-Mail: presse@dso.de

Internet: dso.de

Original-Content von: DSO Deutsche Stiftung Organtransplantation, übermittelt durch news aktuell

Deutsche José Carreras Leukämie-Stiftung e.V.

Die ersten Starzusagen für die 32. José Carreras Gala

Zum 80. Geburtstag von José Carreras übertragen MDR, HR und SWR die Gala live

München/Leipzig (ots)

Weltstar und Stifter José Carreras feiert am 5. Dezember seinen 80. Geburtstag. Das schönste Geschenk sind die vielen Künstlerfreunde, die ihn auch in diesem besonderen Jahr im Kampf gegen Leukämie und verwandten Erkrankungen unterstützen. Mit dem MDR, dem HR und dem SWR übertragen erstmals gleich drei ARD-Rundfunkanstalten Deutschlands emotionalste Benefizgala am Mittwoch, 16. Dezember, ab 20.15 Uhr live aus Leipzig. Parallel ist die Gala im Livestream der ARD-Mediathek zu sehen. David Garrett, Michael Patrick Kelly und Katelyn Harrington, Johnny Logan und der MDR-Kinderchor haben bereits zugesagt.

An der Seite von Gastgeber José Carreras führen wieder die TV-Moderatoren und Stiftungsbotschafter Stephanie Müller-Spirra und Sven Lorig durch den Abend: "José Carreras beweist seit Jahrzehnten, dass seine Stimme nicht nur Menschen musikalisch begeistern, sondern auch Leben verändern und retten kann. Diese Gala ist immer ein Abend voller toller Musik, bewegender Geschichten und gelebter Menschlichkeit. Ihn kurz nach seinem 80.Geburtstag dabei wieder begleiten zu dürfen, ist für uns eine große Ehre, Freude und eine echte Herzensangelegenheit."

Einer der treuesten Unterstützer von José Carreras ist selbst ein Weltstar. Zum elften Mal wird David Garrett zu Gast in der José Carreras Gala sein. "Ich bewundere José Carreras sowohl als Künstler als auch als Initiator der José Carreras Leukämie-Stiftung, die in mehr als drei Jahrzehnten sehr vielen Patienten Hoffnung geschenkt hat. Es ist deshalb für mich eine Herzensangelegenheit, diesen wunderbaren Kollegen zu unterstützen", freut sich David Garrett auf den großen Abend. Als Botschafter der José Carreras Leukämie-Stiftung engagiert sich Garrett auch außerhalb der alljährlichen Gala für den Kampf gegen Leukämie. "Gleichgültigkeit ist keine Option für mich. Ich finde es wichtig, dass sich jeder - im Großen oder im Kleinen - für eine gute Sache einsetzt", sagt Garrett und erzählt, dass er über die Jahre bereits viele Leukämie-Patienten und deren Familien kennengelernt habe: "Diese Menschen sind so unglaublich tapfer, stark, liebevoll und positiv. Das beeindruckt mich jedes Mal zutiefst aufs Neue und ist meine Motivation, den Kampf gegen Leukämie weiter zu unterstützen."

Auch Johnny Logan, dreifacher Gewinner des Eurovision Song Contests als Sänger und Komponist, hat José Carreras bereits mehrfach in der Gala unterstützt. "Ich habe José Carreras 1999 bei einer Preisverleihung kennengelernt und unterstütze seine Mission aus tiefem Herzen. Ich möchte einen kleinen Teil dazu beitragen, jenen Menschen zu helfen, die gerade den härtesten Kampf ihres Lebens führen."

Michael Patrick Kelly stand ebenfalls schon dreimal für den Kampf gegen Leukämie auf der Gala-Bühne. In diesem Jahr wird er gemeinsam mit Katelyn Harrington, der Gewinnerin von The Voice Kids 2026, auftreten. Kelly: "Ich freue mich sehr, bei der diesjährigen Charity Gala dabei zu sein, um die wertvolle Arbeit der José Carreras Leukämie-Stiftung zu unterstützen. Ich durfte schon vor über 30 Jahren zum ersten Mal dabei sein und bin José Carreras und seiner Stiftung seitdem treu geblieben. Ich kenne sehr wenige Menschen, die sich so glaubwürdig engagieren wie er. Nicht nur wegen seiner eigenen Erfahrung mit Leukämie, sondern auch wegen seines unbändigen Einsatzes im Kampf gegen diese Krankheit. Die meiste Arbeit leistet er still im Verborgenen, ohne Medien. José Carreras ist ein Vorbild für mich. Ein Weltstar, dessen Menschlichkeit das Leben vieler nicht nur verlängert, sondern auch gerettet hat."

Katelyn Harrington: "Es ist mir eine große Ehre, zur wunderbaren José Carreras Gala eingeladen worden zu sein und gemeinsam mit Michael Patrick Kelly zu singen. Ich hoffe sehr, dass wir an diesem Abend dazu beitragen können, das Leben positiv zu verändern. Ich danke euch von ganzem Herzen, und möge Gott euch alle segnen."

Im Herzen Mitteldeutschlands zuhause, ist der MDR-Kinderchor das einzige Ensemble seiner Art in Trägerschaft der ARD - mit einer mehr als 75-jährigen, ununterbrochenen Tradition. Der Chor bietet mittlerweile etwa 180 jungen Sängerinnen und Sängern eine musikalische Heimat. Zum vierten Mal, zuletzt im Jahr 2019, werden die Kinder und Jugendliche aus dem Leipziger Chor mit ihren Liedern für schöne musikalische Momente sorgen und die Benefizgala des Startenors José Carreras unterstützen.

Welche weiteren Stars Gastgeber José Carreras auf der Musikbühne und am Spendenpanel in der großen Gala unterstützen, wird in den kommenden Wochen bekanntgegeben. Alle aktuellen Informationen finden Sie unter: www.josecarrerasgala.de

...

Über die Deutsche José Carreras Leukämie-Stiftung

Die José Carreras Leukämie-Stiftung fördert wissenschaftliche Forschungs-, Infrastruktur und Sozialprojekte. 1987 erkrankte Stifter José Carreras an Leukämie. Aus Dankbarkeit über die eigene Heilung gründete er 1995 den gemeinnützigen Deutsche José Carreras Leukämie-Stiftung e.V. und anschließend die dazugehörige Stiftung. Seither wurden bereits über 250 Millionen Euro an Spenden gesammelt und fast 1.600 Projekte finanziert, die den Bau von Forschungs- und Behandlungseinrichtungen, die Erforschung und Heilung von Leukämie und anderer hämato-onkologischer Erkrankungen, die Förderung von jungen Wissenschaftlern im Rahmen von Stipendienprogrammen sowie die Unterstützung der Arbeit von Selbsthilfegruppen und Elterninitiativen zum Ziel haben.

Pressekontakt:

Deutsche José Carreras Leukämie-Stiftung

Presse- und Öffentlichkeitsarbeit

Elisabethstraße 23 | 80796 München

Tel: 089 / 27 29 04 -50

E-Mail: presse@carreras-stiftung.de

Presse I Bildmaterial: Das Logo der José Carreras Gala sowie Bilder

für die Veröffentlichung in anderen Medien in Verbindung mit der José

Carreras Gala sind hier frei verfügbar:

https://www.carreras-stiftung.de/digitale-pressemappe/

Original-Content von: Deutsche José Carreras Leukämie-Stiftung e.V., übermittelt durch news aktuell

Eine neue Ära von Wonka: Ferrero bringt sechs fantasievolle Süßwarenkreationen nach Deutschland. Das neue Wonka-Sortiment von Ferrero ist ab sofort für kurze Zeit deutschlandweit im Handel erhältlich.

Frankfurt am Main (ots)

Ferrero bringt Wonka in den deutschen Handel: Sechs Süßwarenkreationen, von hutförmigen Pralinen über Fruchtgummi-Schnüre aus dem Magic Garden bis zur Oompa-Loompa-Hohlfigur aus Milchschokolade, sind ab sofort deutschlandweit und für begrenzte Zeit erhältlich. Mit dem Sortiment schlägt das Unternehmen ein neues Kapitel in der Geschichte der Wonka-Süßwaren auf.

Mit dem neuen Sortiment will Ferrero den Alltag ein wenig außergewöhnlicher machen und überrascht mit außergewöhnlichen Kombinationen aus Geschmack, Farbe und Textur. Inspiriert ist es von der Fantasie, der Neugier und dem Entdeckergeist, die Wonkas Welt prägen.

Ein Goldenes Ticket für Ferrero

Was passiert, wenn Cola-Geschmack und Knallzucker auf Schokolade treffen? Oder wenn Karamellgeschmack und Himbeergeschmack kombiniert wird? Das klingt nach Experimenten direkt aus Wonkas Welt und steht zugleich für eine neue Generation von Süßwaren, die dank Ferrero weltweit in den Handel kommt.

Ferrero sicherte sich im Jahr 2018 die exklusiven Süßwarenrechte an der Marke Wonka und erhielt damit sein ganz persönliches "Goldenes Ticket". Doch einen Namen wie "Wonka" zu tragen, bedeutet mehr, als ein bekanntes Logo auf eine Schokoladentafel zu drucken. Der vor mehr als 60 Jahren erschaffene Willy Wonka steht heute sinnbildlich für außergewöhnliche Süßwaren, überraschende Geschmackserlebnisse und fantasievolle Kreationen.

Hinter den Kulissen haben Ferreros Forschungs- und Entwicklungsteams daran gearbeitet, dieses legendäre Universum mit viel Sorgfalt zum Leben zu erwecken. Gemeinsam mit den Kreativteams des Unternehmens erprobten sie Rezepte, Aromen, Texturen und Formen, um herauszufinden, wie sich Wonkas berühmtes Staunen in echte Genussmomente übersetzen lässt. Nun können Verbraucherinnen und Verbraucher in Deutschland entdecken, woran die Teams gearbeitet haben.

Sechs Kreationen voller Überraschungen

Ob gefüllte Schokolade, Gummibonbons mit fruchtigem Geschmack oder Sammelfiguren: Das neue Wonka-Sortiment macht die Welt aus Büchern und Filmen auf unterschiedliche Weise erlebbar.

Wonka Magic Hats: Die farbenfrohen, hutförmigen Pralinen gibt es in vier Geschmacksrichtungen: "Chocolonka" kombiniert Milchschokolade mit knusprigen Kakaoflakes, "Caramellion" verbindet Schokolade und Karamellgeschmack mit knusprigen Maisstückchen und "Magenta Elixir" ergänzt Karamellgeschmack um eine spritzige Himbeernote. "Choco Fizz" vereint Schokolade mit einer prickelnden Füllung mit Cola-Geschmack.

Wonka Purplypurple Milchschokoladentafel: Die cremige 90-g-Tafel aus Milchschokolade enthält eine Milchcremefüllung mit Karamellgeschmack in Wonkas legendärem Lila. Nach Angaben von Ferrero ist es die weltweit erste lila Karamellfüllung im Handel.

Wonka Magic Garden Ropes: Die vom Garten in Wonkas Schokoladenfabrik inspirierten Gummibonbonsticks mit Zitronen- und Limettengeschmack bringen viel Zitrus-Pep mit. Außen bissfest, innen weicher: Die kontrastierenden Texturen und der saure Geschmack machen jeden Bissen besonders.

Wonka Oompa-Loompa Milchschokoladen-Hohlfigur: Die Hohlfiguren aus zarter Milchschokolade sind von Wonkas berühmten Fabrikarbeitern inspiriert und dank ihrer grünen Haare und markanten weißen Augenbrauen sofort als Oompa-Loompas zu erkennen.

Wonka Oompa-Loompa Gummies: Die Gummies mit fruchtigem Geschmack in Form der Oompa-Loompas verbinden Erdbeer- und Heidelbeergeschmack mit einer Füllung mit intensivem Himbeer-Cola-Geschmack.

Wonka kinder Joy: In kinder Joy stecken jetzt sammelbare Wonka-Funko-Figuren. Neben der Kombination aus zarter Milch- und Kakaocreme und knusprigen Konfekten wartet in einigen Eiern eine besondere Überraschung: eine seltene goldfarbene Wonka-Figur.

Die Magie von Wonka bei jedem Bissen

"Wir freuen uns sehr, dass das Wonka-Süßwarensortiment nun im Handel zu finden ist. Diese Produktfamilie lädt Fans dazu ein, das Wonka-Universum auf neue Weise zu entdecken und zu erleben. Bei Ferrero fühlen wir uns geehrt, eine so beliebte und nostalgische Marke zum Leben erwecken zu dürfen. Dabei greifen wir auf Ferreros jahrzehntelange Expertise und Kreativität zurück. Wir hoffen, dass Fans diese Produkte genauso lieben werden, wie wir es geliebt haben, sie zu entwickeln, und vor allem, dass sie die Magie des Wonka-Universums bei jedem Bissen schmecken", sagt Katharina Büge, Head of Business Planning & Development bei Ferrero Deutschland.

Das ist erst der Anfang

Aus Wonkas Erfinderwerkstatt kommt noch mehr: Eis und weitere Kreationen aus verschiedenen Kategorien befinden sich bereits in der Entwicklung. So hält jede Saison, von Weihnachten über Ostern bis hin zu Sommer und Halloween, eine neue Geschmacksrichtung, eine neue Produktform oder eine weitere Kreation bereit. Was als Nächstes erscheint, bleibt ganz im Wonka-Stil ein köstliches Geheimnis.

Über Ferrero

Das Familienunternehmen Ferrero begann 1946 als Konditorei in Alba, Italien, und hat sich seitdem zu einem der weltweit größten Hersteller von Süßwaren und verpackten Genussprodukten entwickelt, dessen Produkte in mehr als 170 Ländern verkauft werden. 2018 erwarb Ferrero die exklusiven Süßwarenrechte an der Marke Wonka.

Pressekontakt:

Unternehmenskontakt:

Ferrero Deutschland GmbH

Hainer Weg 120

60599 Frankfurt am Main

Telefon:069/68 05-0

Fax:069/68 05-288 0

Agenturkontakt:

PUNKT Gesellschaft für Public Relations mbH

Benjamin Kolthoff

Völckersstraße 44

22765 Hamburg

Tel.: +49 40 853760-11

Fax: +49 40 853760-10

E-Mail: bkolthoff@punkt-pr.de

Original-Content von: Ferrero Deutschland, übermittelt durch news aktuell

ZDF, 3sat und phoenix berichten von der UN-Klimakonferenz 2026

Mainz (ots)

In Antalya findet vom 9. bis zum 20. November 2026 die 31. Weltklimakonferenz, die COP31, statt. Das ZDF, 3sat und phoenix berichten in Nachrichten- und Magazinsendungen sowie in Dokumentationen über die Konferenz. Vor Ort sind die ZDF-Reporterinnen Winnie Heescher und Elisa Miebach für die ZDF-Umweltredaktion und "NANO"-Moderator Gregor Steinbrenner für 3sat.

Die Türkei übernimmt die Gastgeberrolle für die COP31, während Australien den Vorsitz der Verhandlungen führt. Die geteilte Präsidentschaft bringt verschiedene Perspektiven in die Diskussionen ein. Gerade der Pazifikraum mit seinen Inselstaaten ist besonders von den Klimaveränderungen bedroht. Besonders Umsetzung und Finanzierung von Projekten werden in diesem Jahr stark diskutiert werden.

ZDFheute mit dem KlimaRadar und weiteren Infos

Das Online-Nachrichtenangebot ZDFheute stellt mit Faktenchecks und Übersichtsartikeln dar, was in Antalya diskutiert wird. Ein Update des KlimaRadar von ZDFheute, Infos zum neuen Klimaschutz-Index und weitere Fragen und Antworten zur UN-Klimakonferenz kommen hinzu. Auf den Social-Media-Kanälen des ZDF begleiten Reels, Galerien und Grafiken die Konferenz.

"Volle Kanne – Service täglich"

"Volle Kanne – Service täglich", montags bis freitags von 9.05 bis 10.30 Uhr, berichtet vom 9. bis zum 20. November 2026 kontinuierlich über die UN-Klimakonferenz – in aktuellen Stücken und Schalten zum ZDF-Team vor Ort in Antalya.

Zwei "planet e."-Dokumentationen

Die "planet e."-Dokumentation "Drei Wege – wie Klimazukunft gemacht wird" fragt am Sonntag, 8. November 2026, 15.30 Uhr, im ZDF und ab Freitag, 6. November 2026, 8.30 Uhr, im ZDF-Streaming-Portal, wie Deutschland, Indien und Äthiopien mit ihren unterschiedlichen Ausgangslagen den Herausforderungen durch den Klimawandel begegnen. Deutschland ringt um die Transformation seiner Industrie, Indien um Wachstum und steigenden Energiebedarf. Äthiopien setzt in seiner Verkehrsstrategie auf E-Mobilität. Die ZDF-Korrespondenten Susann von Lojewski, Johannes Hano, Winnie Heescher und Andreas Stamm zeigen, wie Klimaschutz, wirtschaftliche Entwicklung und politische Interessen miteinander verwoben sind und warum die Antworten auf die Klimakrise so unterschiedlich ausfallen.

Weltklimakonferenzen bringen zu wenig Erfolge, sagen Kritiker. Doch bislang gibt es keine Alternativen. Anlässlich der COP31 beschreibt und analysiert die "planet e."-Dokumentation "Klima – die Welt verhandelt ihre Zukunft" am Sonntag, 15. November 2026, 15.30 Uhr, im ZDF und ab Freitag, 13. November 2025, 8.30 Uhr, im ZDF-Streaming-Portal, die Verhandlungen und Austauschprozesse. Autor Andreas Weise begleitet die Konferenzteilnehmer und spiegelt das Geschehen in Antalya.

Die Dokumentation "Mission Pinguin – Mit dem Segelboot in die Antarktis"

Im Segelboot unterwegs ans Ende der Welt: ZDF-Reporter Carsten Behrendt begleitet in seinem Film "Mission Pinguin – Mit dem Segelboot in die Antarktis" am Sonntag, 8. November 2026, 16.15 Uhr, im ZDF und ab Sonntag, 1. November 2026, 10.00 Uhr, im ZDF-Streaming-Portal eine außergewöhnliche Expedition in die Antarktis. Mit dabei: Profisegler Boris Herrmann. Die Mission hat eine besondere Bedeutung. Die Danger-Inseln wurden auf Initiative Deutschlands und der USA unter besonderen Schutz gestellt. Nun wollen die Wissenschaftler des Umweltbundesamts, des Alfred-Wegener-Instituts und des Thüringer Instituts für Nachhaltigkeit und Klimaschutz den Zustand der sieben Inseln und ihrer Tierwelt umfassend dokumentieren.

Die lange Nacht zur Klimakonferenz

Die lange Nacht zur Klimakonferenz am Mittwoch, 18. November 2026, von 0.30 bis 4.15 Uhr im ZDF, bündelt noch einmal alle aktuellen Dokumentationen zur COP31 und wiederholt darüber hinaus "Terra X: Harald Lesch", "plan b" und weitere "planet e."-Dokumentationen, die sich mit dem Thema Klima befassen.

Das Programm in 3sat

Das 3sat-Wissenschaftsmagazin "NANO" berichtet ab Montag, 9. November 2026, werktäglich um 18.30 Uhr über die UN-Klimakonferenz. Moderator Gregor Steinbrenner ist vor Ort und ordnet die Geschehnisse rund um den Gipfel ein. Im Vorfeld der COP31 ist in der 3satMediathek ab Donnerstag, 5. November 2026, die dreiteilige NANO-Reportagereihe "Water Warriors" verfügbar. Sie begleitet Wissenschaftler, Landwirte und Start-ups rund ums Mittelmeer, die mit innovativen Technologien nachhaltige Lösungen für die Wasserkrise entwickeln. Eine Spezial-Ausgabe von "NANO" beschäftigt sich am Montag, 9. November 2026, 18.30 Uhr, mit der Frage: Macht die Klimapolitik endlich ernst? Am Donnerstag, 12. November 2026, ab 20.15 Uhr, widmen sich "NANO Doku" und "NANO Talk" an einem Wissenschaftsabend den Themen "Waldbrände: Leben mit dem Feuer" und "Klimakrise – Unser neues Normal?". Die wichtigsten Ergebnisse der 31. Klimakonferenz fasst "NANO" am Montag, 23. November 2026, um 18.30 Uhr in einem Abschlussbericht zusammen.

Die Pressekonferenzen der COP31 auf phoenix

phoenix berichtet wie gewohnt von den Verhandlungen bei der Klimakonferenz und zeigt die wichtigsten Pressekonferenzen.

Kontakt

Bei Fragen zur Sendung erreichen Sie Magda Huthmann telefonisch unter 06131 – 70-12149 oder per E-Mail unter huthmann.m@zdf.de sowie Christina Betke telefonisch unter 06131 – 70-12717 oder per E-Mail unter betke.c@zdf.de.

Sie erreichen die ZDF-Kommunikation telefonisch unter 06131 – 70-12108 oder per E-Mail unter pressedesk@zdf.de.

Pressefotos

Pressefotos zur Sendung erhalten Sie als Download (nach Log-in), telefonisch unter 06131 – 70-16100 oder per E-Mail unter pressefoto@zdf.de.

Weitere Informationen

- Für akkreditierte Journalistinnen und Journalisten steht die Doku "Mission Pinguin – Mit dem Segelboot in die Antarktis" zur Preview im ZDF-Presseportal (nach Log-in) zur Verfügung.

- Presseinformationen im ZDF-Presseportal

- Presseinformationen zu " Mission Pinguin – Mit dem Segelboot in die Antarktis"

- Presseinformationen im 3sat-Pressetreff

- planet e. im ZDF-Streaming-Portal

Pressekontakt:

ZDF-Kommunikation

pressedesk@zdf.de

Folgen Sie uns gerne auch bei LinkedIn (https://www.linkedin.com/company/zdf/).

Original-Content von: ZDF, übermittelt durch news aktuell

AskGamblers Launches a New Casino Complaints Dashboard

News provided by

AskGamblers

Oct 29, 2026, 05:49 ET

The new Casino Complaints Dashboard provides a transparent, evidence-based view of the complaints handled by the AskGamblers Casino Complaint Service (AGCCS).

BELGRADE, Serbia, Oct. 29, 2026 /PRNewswire/ -- AskGamblers, a leading iGaming affiliate website, has launched a new online casino complaints dashboard that lets players access more information from the AskGamblers Casino Complaint Service (AGCCS), which mediates between operators and users.

The dashboard visualises general stats, resolution processes, casino rankings, common issues players face, current trends, money recovered and affiliate program complaints statistics.

Players can filter information by choosing different periods, from seven days to one year or view all-time historical data, dating back to 2009 when the service was established.

The Casino Complaints Dashboard updates in real time as complaints are submitted and resolved, so everyone has the latest information available.

Dijana RadunoviÄ, General Manager at AskGamblers, said: "With the new dashboard, players can access data in real time, find out which casinos receive complaints, how much money is recovered, how affiliate programs perform, and identify or analyse trends."

RadunoviÄ added: "Players trust AGCCS; they've done so since 2009. But they haven't had insight into our data, except through historical data, quarterly and annual reports. With the new dashboard, they see what we see. We aim to be as transparent as possible and invite players experiencing issues with operators to submit their disputes to our team."

To explore the data, visit the new dashboard here.

About AskGamblers

AskGamblers.com strives to provide current, objective, and accurate information and guide its users towards a safe gaming experience. The way we deliver our services, from the online casino, slot, and bonus reviews to our trusted Complaint Service, is best described by our motto: "Get the truth. Then play."

For any queries regarding AskGamblers, please get in touch with [email protected].

This information was brought to you by Cision http://news.cision.com.

Signed LTAs valued at multiple billions of dollars with minimum volume commitments

- Total company orders1 up ~35%; Commercial HVAC1 up ~60%; data centers up ~300%

- Record >$8.5B backlog; LTA minimums additive to backlog

- Net sales up 12%; organic sales up 15%

- GAAP EPS2 of ($3.16); adjusted EPS2 of $0.87

- Net cash flows from operating activities of $813 million and free cash flow of $674 million

- Returned ~$600 million to shareowners through dividends and repurchases

PALM BEACH GARDENS, Fla., Oct. 29, 2026 /PRNewswire/ -- Carrier Global Corporation (NYSE: CARR), global leader in intelligent climate and energy solutions, today reported financial results for the third quarter of 2026.

"We delivered strong third quarter performance, with orders, sales and adjusted EPS all up between 15% and 35%, with very strong free cash flow," said Chairman & CEO David Gitlin. "Organic orders were up ~35%, with data center orders up ~300%, resulting in over $8.5 billion of backlog, up 60% versus last year, reflecting continued strong demand for our differentiated solutions. We expect to deliver double-digit organic sales and adjusted EPS growth in 2026, while record backlog levels give us confidence to sustain this momentum into 2027 and beyond."

Third Quarter 2026 Results

Total Company

Carrier's third quarter sales of $6.3 billion increased 12% compared to the prior year. Organic sales increased 15%, and divestitures were a headwind of 3%.

GAAP operating loss of ($2,273) million in the quarter decreased from last year, with growth in all segments offset by a goodwill impairment charge.

Adjusted operating profit of $1,091 million in the quarter increased 33% with growth in all segments.

Adjusted operating margin of 17.4% was up 260 basis points from last year, predominantly due to favorable volume and price partially offset by the impact of increased input costs and tariffs.

The company recorded approximately $130 million of operating profit benefit from IEEPA refunds.

Net loss from continuing operations was ($2,593) million and adjusted net earnings from continuing operations were $713 million. GAAP EPS from continuing operations was ($3.16) and adjusted EPS was $0.87. The increase in adjusted EPS was primarily driven by higher operating profit and the benefits of a lower share count, partially offset by a higher effective tax rate and higher non-controlling interest related to the IEEPA refunds.

Climate Solutions Americas (CSA)

CSA segment sales grew 24%. Organic sales were up 25%, driven by strong Residential and Commercial1 performance, up over 30% and 25%, respectively.

Segment operating margin expanded 250 basis points from the benefit of ~$120 million of IEEPA refunds and organic growth, partially offset by increased input costs and tariffs.

Climate Solutions Europe (CSE)

CSE segment sales increased 3% with strong organic sales growth of 12% offset by a 7% net headwind from divestitures and a 2% headwind from currency. Residential and Light Commercial (RLC) sales increased low-teens and Commercial grew high-single digits. Strong demand in residential heat pumps and air conditioning continued, with sales up ~35% each, more than offsetting high-single digit declines in boilers.

Segment operating margin increased 330 basis points with strong organic revenue growth and a ~100 basis point net benefit from the correction of a prior period item offset by increases in inventory-related reserves.

Climate Solutions Asia Pacific, Middle East & Africa (CSAME)

CSAME segment sales increased 2%. Organic sales were up 3% driven by strong growth in Commercial, up 10%, partially offset by a mid-single-digit decline in RLC.

Segment operating margin increased 50 basis points.

Climate Solutions Transportation (CST)

CST sales decreased 3% as continued growth in Container was more than offset by Truck and Trailer.

Segment operating margin increased 70 basis points driven by the benefits from IEEPA refunds partially offset by lower volumes.

Cash Flow

Net cash flows generated from operating activities were $813 million, and capital expenditures were $139 million, resulting in free cash flow of $674 million.

Goodwill

During Q3, the company recorded a non-cash goodwill impairment charge of $3.1 billion related to its Climate Solutions Europe reporting unit.

Full-Year 2026 Guidance**

Supported by a differentiated product portfolio, record backlog, minimum volume commitments under long-term agreements, and continued recovery in RLC end markets, Carrier now expects sales of nearly $24 billion, with organic growth of approximately 10%. The company remains vigilant in navigating industry-wide macro pressures, including tariffs and increasing input costs, and expects to return to shareowners approximately $2.3 billion through dividends and share repurchases.

**As of October 29, 2026

Conference Call

Carrier will host a webcast of its earnings conference call today, Thursday, Oct. 29, 2026, at 7:30 a.m. ET. To access the webcast, visit the Events & Presentations section of the Carrier Investor Relations site. For alternative dial-in information, please contact Carrier investor relations at [email protected].

Cautionary Statement

This communication contains statements which, to the extent they are not statements of historical or present fact, constitute "forward-looking statements" under the securities laws. From time to time, oral or written forward-looking statements may also be included in other information released to the public. These forward-looking statements are intended to provide management's current expectations or plans for our future operating and financial performance, based on assumptions currently believed to be valid. Forward-looking statements can be identified by the use of words such as "believe," "expect," "expectations," "plans," "strategy," "prospects," "estimate," "project," "target," "anticipate," "will," "should," "see," "guidance," "outlook," "confident," "scenario" and other words of similar meaning in connection with a discussion of future operating or financial performance. Forward-looking statements may include, among other things, statements relating to future sales, earnings, cash flow, results of operations, uses of cash, expectations relating to our sales backlog, commitments by us and our customers under long-term agreements, share repurchases, tax rates and other measures of financial performance or potential future plans, strategies or transactions of Carrier, market conditions including with respect to residential end-markets, data center and otherwise, growth prospects for 2026 and beyond, expectations concerning the mitigation and net impact of tariffs during 2026, Carrier's guidance for full-year 2026, Carrier's plans with respect to our indebtedness and other statements that are not historical facts. All forward-looking statements involve risks, uncertainties and other factors that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the U.S. Private Securities Litigation Reform Act of 1995. Such risks, uncertainties and other factors include, without limitation, those described below and under the section titled "Risk Factors" in our most recent Annual Report on Form 10-K and in subsequent reports that we file with the SEC: the effect of economic conditions in the industries and markets in which Carrier and our businesses operate in the U.S. and globally and any changes therein, including financial market conditions, inflationary cost pressures, fluctuations in commodity prices, interest rates and foreign currency exchange rates, levels of end market demand in construction, the impact of weather conditions, pandemic health issues, natural disasters and the financial condition of our customers and suppliers; challenges in the development, production, delivery, support, performance and realization of the anticipated benefits of advanced technologies and new products and services; future levels of capital spending and research and development spending; future availability of credit and factors that may affect such availability, including credit market conditions and Carrier's capital structure and credit ratings; the timing and scope of future repurchases of Carrier's common stock, including market conditions and the level of other investing activities and uses of cash; delays and disruption in the delivery of materials and services from suppliers; cost reduction efforts and restructuring costs and savings and other consequences thereof; new business and investment opportunities; the outcome of legal proceedings, investigations and other contingencies; the impact of pension plan assumptions on future cash contributions and earnings; the impact of the negotiation of collective bargaining agreements and labor disputes; the effect of changes in political conditions in the U.S. and other countries in which Carrier and our businesses operate, including the effect of ongoing uncertainty and/or changes in U.S. trade policies, on general market conditions, global trade policies, the imposition of tariffs, and currency exchange rates in the near term and beyond; the effect of changes in tax, environmental, regulatory (including among other things import/export) and other laws and regulations in the U.S.

RANCHO CUCAMONGA, Calif., October 29, 2026 /PRNewswire/ -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that the Company will release results for its third quarter of 2026 ended September 30, 2026, after the market closes on Thursday, November 5, 2026, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time.

To access the conference call, dial toll-free 877-407-0989, for international calls, dial 201-389-0921, ten minutes before the conference.

The call can also be accessed on the Investors page on the Company's website www.amphastar.com. The webcast replay of the call will be available on our Company website within 24 hours after the end of the live conference call.

About Amphastar Pharmaceuticals, Inc.

Amphastar is a biopharmaceutical company that focuses on developing, manufacturing, and commercializing technically challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Company sells active pharmaceutical ingredient, or API products. Most of the Company's finished products are contracted and distributed through group purchasing organizations, drug wholesalers, and drug retailers. More information and resources are available at www.amphastar.com.

Amphastar's logo and other trademarks or service marks of Amphastar, including, but not limited to Amphastar®, BAQSIMI®, Primatene MIST®, Amphadase®, and Cortrosyn®, are the property of Amphastar.

Forward Looking Statements

All statements in this press release and in the conference call referenced above that are not historical are forward-looking statements, including, among other things, statements relating to our expectations regarding future financial performance and business trends, our future growth and our ability to continue to scale, sales and marketing of our products, market size and expansion, product portfolio, product development, the timing of FDA filings or approvals, the timing of product launches, acquisitions and other matters related to our pipeline of product candidates, the timing and results of clinical trials, the impact of our products, including their potential for continued revenue growth, the strategic trajectory of and market for our product pipeline, our long-term strategic vision, our ability to leverage our existing expertise and technology, the impacts of any licensing agreements and ability to commercialize additional therapies, our in-house manufacturing expertise, our ability to deliver high quality, affordable therapies to patients, our commercial momentum and position in the market. These statements are not facts but rather are based on Amphastar's historical performance and our current expectations, estimates, and projections regarding our business, operations, and other similar or related factors. Words such as "may," "might," "will," "could," "would," "should," "anticipate," "predict," "potential," "continue," "expect," "intend," "plan," "project," "believe," "estimate," and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Amphastar's control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in Amphastar's filings with the Securities and Exchange Commission ("SEC"), including in our Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on February 26, 2026, in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, filed with the SEC on May 7, 2026, in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, filed with the SEC on August 6, 2026, and our other filings or reports that we may file with the SEC. In particular, there can be no guarantee that our sales strategies will be successful, or that we will continue to experience significant sales of BAQSIMI®. You can locate these reports through our website at http://ir.amphastar.com and on the SEC's website at www.sec.gov. The forward-looking statements in this release speak only as of the date of the release. Amphastar undertakes no obligation to revise or update information or any forward-looking statements in this press release or the conference call referenced above to reflect events or circumstances in the future, even if new information becomes available or if subsequent events cause our expectations to change.

SOURCE Amphastar Pharmaceuticals, Inc.

Share this article

Raising Full-Year Net Sales and Adjusted-Diluted EPS guidance

EXTON, Pa., Oct. 29, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a leading provider of innovative, high-quality injectable solutions and services, today announced its financial results for the third quarter of 2026.

Third-Quarter 2026 Summary (comparisons to prior-year period)

- Net sales of $874.5 million increased 8.7%; organic growth was 11.9%.

- Diluted earnings per share ("EPS") of $3.02 increased 57.3%.

- Adjusted-diluted EPS of $2.66 increased 35.7%.

- The Company repurchased $231 million of stock in the quarter, bringing the year-to-date total to $685 million.

- Year-to-date operating cash flow was $403 million. Capital expenditures were $125 million.

- The Company also announced on October 19, 2026, that its Board of Directors declared a fourth-quarter dividend of $0.26 per share, an increase of 18% over the $0.22 per share paid in the prior quarter.

Outlook for Full-Year 2026

- Full-year 2026 net sales guidance increased to a range of $3.41 billion to $3.42 billion, up from the previous range of $3.345 billion to $3.380 billion.

- Full-year 2026 adjusted-diluted EPS guidance increased to a range of $9.38 to $9.48, up from the previous range of $8.85 to $9.05.

Michel Lagarde, President and Chief Executive Officer, commented: "I am pleased to report strong third-quarter 2026 results, with net sales and adjusted EPS exceeding our expectations. Our results were again led by our High-Value Product (HVP) Components business. The robust sales performance drove strong operating income margin expansion and EPS growth. As a result of our team's strong execution in the third quarter, we are increasing our full-year 2026 guidance."

Mr. Lagarde concluded: "I want to thank our global teams for their relentless focus on execution to deliver products and services for our customers and the patients they serve. West is a critical primary containment and drug delivery partner for pharmaceutical companies, biotechs and CDMOs around the world. We are grateful for the trust our customers put in us, and we remain committed to driving continuous improvement to even better serve their current and future needs."

Proprietary Products Segment

Net sales of $728.8 million grew by 12.6% and increased 16.6% on an organic basis.

- High-Value Product ("HVP") Components net sales of $466.7 million increased 19.7% and rose 20.3% on an organic basis. HVP Components accounted for 53% of total company net sales in the quarter.

- HVP Delivery Devices net sales of $99.1 million were flat, and were up 26.4% on an organic basis excluding foreign currency translation effects and the impact of the divestiture of SmartDose® 3.5mL. HVP Delivery Devices accounted for 11% of total company net sales in the quarter.

- SmartDose® 3.5mL net sales represented $11.8 million in the quarter and $29.8 million in the prior-year quarter and are excluded from both periods to calculate organic growth.

- Standard Products net sales of $163.0 million increased by 2.9% and rose 3.1% on an organic basis. Standard Products accounted for 19% of total company net sales this quarter.

West Vantage Segment

Net sales of $145.7 million decreased by 7.3% and declined 6.6% on an organic basis. West Vantage accounted for 17% of total company net sales in the quarter.

Full-Year 2026 Financial Guidance

- The Company is increasing its full-year 2026 net sales guidance range to $3.41 billion to $3.42 billion, up from the previous range of $3.345 billion to $3.380 billion.

- Organic net sales growth guidance increased to a range of 11.3% to 11.6%, up from the prior range of 10% to 11%.

- SmartDose® 3.5mL generated $55.3 million in net sales in the second half of 2025 and generated $11.8 million in net sales in the third quarter of 2026. No additional SmartDose® 3.5mL product sales are expected for the remainder of the year. These net sales are excluded in both periods to calculate full-year 2026 organic growth.

- The Company is increasing its full-year 2026 adjusted-diluted EPS guidance range to $9.38 to $9.48, up from the previous range of $8.85 to $9.05.

- Full-year 2026 capital spending guidance is updated to a range of $215 million to $220 million, down from the prior range of $250 million to $275 million.

Third-Quarter 2026 Conference Call 

Management will host a conference call at 8 a.m. EDT today. The live webcast can be accessed in the "Investors" section of the Company's website by clicking here.

To participate in the Q&A portion of the conference call, please register in advance by clicking here.

Registered telephone participants will receive the dial-in number along with a unique PIN number that will enable them to ask questions on the call.

An accompanying slide presentation will be posted in the "Investors" section of the Company's website.

A replay of the webcast will be available on the Company's website for approximately 90 days after the event.

About West

West Pharmaceutical Services, Inc. is a leading provider of innovative, high-quality injectable solutions and services. As a trusted partner to established and emerging drug developers, West helps ensure the safe, effective containment and delivery of life-saving and life-enhancing medicines for patients. With over 10,000 team members across 50 sites including 26 manufacturing facilities worldwide, West helps support our customers by delivering over 41 billion components and devices each year. Headquartered in Exton, Pennsylvania, West in its fiscal year 2025 generated $3.07 billion in net sales. West is traded on the New York Stock Exchange (NYSE: WST) and is included in the Standard & Poor's 500 index. For more information, visit www.westpharma.com.

All trademarks and registered trademarks used in this release are the property of West Pharmaceutical Services, Inc. or its subsidiaries, in the United States and other jurisdictions, unless otherwise noted.

Daikyo®, Daikyo Crystal Zenith® and Daikyo CZ® are registered trademarks of Daikyo Seiko, Ltd. Daikyo Crystal Zenith technologies are licensed from Daikyo Seiko, Ltd. 

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the Company's expectations regarding future events, financial guidance and financial or operational performance. Forward-looking statements may be identified by words such as "believe," "expect," "intend," "estimate," "plan," "anticipate," "project," "forecast," "guidance," "target," "may," "will," "continue" and similar expressions.

These statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. For additional information regarding these risks as well as other risks, uncertainties and factors that could affect our forward-looking statements, please refer to Part I Item 1A, entitled "Risk Factors," of the Company's most recent Annual Report on Form 10-K and any amendments thereto, as well as the Company's most recently filed Quarterly Reports on Form 10-Q and other filings the Company makes with the Securities and Exchange Commission.

Forward-looking statements speak only as of the date of this press release. Except as required by law or regulation, West Pharmaceutical Services, Inc. undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Non-U.S. GAAP Financial Measures

The Company reports its financial results in accordance with U.S. generally accepted accounting principles ("U.S. GAAP"). However, management also uses certain non-U.S. GAAP financial measures in evaluating our results of operations. Management believes that this information provides users with a valuable insight into our overall performance and financial position. As a result, this release contains certain non-GAAP financial measures, including organic net sales, adjusted-diluted EPS and adjusted operating profit. Organic net sales exclude the impact from acquisitions and/or divestitures and translate the current-period reported sales of subsidiaries whose functional currency is other than the U.S. Dollar at the applicable foreign currency exchange rates in effect during the comparable prior-year period. We may also refer to financial results, such as adjusted-diluted EPS and adjusted operating profit, that exclude the effects of unallocated items. The unallocated items are not representative of ongoing operations, and generally include restructuring and related charges, certain asset impairments, and other specifically identified income or expense items. These non-U.S. GAAP financial measures should be viewed in addition to, and not as an alternative for, the Company's results prepared in accordance with U.S. GAAP. A reconciliation of these non-U.S. GAAP measures to the comparable U.S. GAAP financial measures is included in the accompanying tables.

SOURCE West Pharmaceutical Services, Inc.

Share this article

Founder and CEO Kathryn Wilson also named one of the Top 10 Inspiring Women Entrepreneurs to Watch in 2026

BOSTON, Oct. 29, 2026 /PRNewswire/ -- VUE Health, an independent healthcare advertising agency that helps emerging biopharma companies bring breakthrough therapies to market, has been named Healthcare Advertising Agency of the Year 2026 by Healthcare Business Review. The publication featured VUE Health as its cover story, "VUE Health: The Creative Architects Behind Tomorrow's Breakthrough Medicines." In a second milestone, VUE Health Founder and CEO Kathryn Wilson has been named one of the Top 10 Inspiring Women Entrepreneurs to Watch in 2026.

Key facts about VUE Health

- Recognition: Healthcare Advertising Agency of the Year 2026 (Healthcare Business Review); Founder and CEO Kathryn Wilson named one of the Top 10 Inspiring Women Entrepreneurs to Watch in 2026 (MSN)

- What VUE Health is: A healthcare advertising and medical communications agency focused on helping innovative therapies reach the people who need them

- Who VUE serves: Emerging biopharma companies commercializing therapies in oncology, rare disease, central nervous system conditions, and novel delivery technologies

- Leadership: Kathryn Wilson, Founder and CEO; Vikram Kanda, PhD, Chief Medical Officer and Partner

Why VUE Health Was Named Healthcare Advertising Agency of the Year 2026

The Healthcare Business Review recognition cites VUE Health's ability to combine deep scientific expertise, strategic insight, and creative execution to help innovative therapies move from development into meaningful patient impact.

VUE Health was built on a simple premise: put senior expertise back into the work. Unlike the traditional model, in which senior executives win the business and hand it to junior teams, VUE Health's experienced strategists, scientists, medical professionals, and creative leaders stay closely involved with clients throughout the commercialization journey. Clients have come to call VUE Health the "non-agency agency": no layers and senior people who work as true partners.

What sets VUE Health apart

- Science at the foundation. A multidisciplinary medical team of PhDs and PharmDs works alongside strategy and creative, so scientific understanding stays central to every program

- Sync Sprint methodology. VUE Health's approach can bring a product or program to market in as little as 90 days when circumstances demand it, starting with deep scientific immersion, market understanding, and strategic alignment before execution accelerates

- Proven launch impact. For a rare disease therapy for Castleman disease, which was facing limited awareness and widespread misdiagnosis, VUE Health prepared for launch in about 90 days. Its interactive "castle" experience at the American Society of Hematology (ASH) annual meeting helped drive 99.8% recall of 5 key messages among participants, and the product saw 33% month-over-month, year-over-year sales growth

- AI-enabled, human-led. VUE Health uses technology to enhance human expertise rather than replace it, including internal platforms for workflow and resource management, a proprietary capability that assembles custom teams from employees and a network of vetted experts, and AI tools that make scientific dialogue with key opinion leaders faster and more meaningful

- Focused on what matters most. VUE Health concentrates on emerging biopharma companies in categories where awareness, diagnosis, and clinical education are often the critical barriers. The agency continues to expand its capabilities across media, public relations, technology platforms, and specialized scientific expertise

Kathryn Wilson: Top 10 Inspiring Women Entrepreneurs to Watch in 2026

Wilson founded VUE Health after rising through senior agency roles and finding herself spending less time solving clients' commercialization challenges and more time managing P&Ls and operations. She built VUE Health to return senior talent to the work itself, and that model now defines the agency's identity. MSN's feature highlights her decades of experience translating complex science into clear, meaningful communication for healthcare professionals and patients and a leadership style grounded in integrity, empathy, and meaningful impact. Her path into the industry began with an early pharmaceutical advertising internship that sparked a lasting passion, and today she is committed to supporting communities and developing future women leaders.

"I built the agency because I wanted to get back to the work that brought me into this industry in the first place, helping companies solve difficult challenges and bringing life-changing and lifesaving medicines to market," said Kathryn Wilson, Founder and CEO of VUE Health.

A Recognition Built by the VUE Health Team

"These honors belong to every person at VUE Health," said Wilson. "Agency of the Year recognizes what our team does every day: our medical team, strategists, creatives, media and account leaders, and the vetted experts who partner with us. My own recognition is really a reflection of the people who chose to build something different with me. We are not trying to become the biggest agency. We are focused on becoming the right partner for companies developing therapies where our experience, expertise, and passion can truly make a difference."

Wilson and VUE Health Chief Medical Officer and Partner Vikram Kanda, PhD, a scientist trained in molecular cardiology, work closely with clients as strategic peers, a model especially valuable for emerging biopharma companies whose first commercial hires are often building a launch with limited internal support.

"Pharmaceutical commercialization depends on scientific accuracy, clinical relevance, and a deep understanding of how healthcare decisions are made," said Dr. Kanda. "Our medical team makes sure the science is never separated from the story. That is what this recognition is about: a team that slows down first to understand the science so our clients can move faster later."

VUE Health also thanks:

- Vikram Kanda, PhD, Partner and Chief Medical Officer and the medical team for best-in-class medical strategy and education

- Meaghan Taft, SVP Client Service and the strategy and account teams for ensuring commercial excellence

- Ohad Cohen, Executive Creative Director and the creative team for hard-hitting and targeted creative and pull-through to impact the attention of the HCP

- Dan Hurley, SVP Innovation and the omnichannel media team for strategic implementation and execution of omnichannel launch excellence and optimization

About VUE Health

VUE Health is an independent healthcare advertising agency that helps emerging biopharma companies bring breakthrough therapies to market. Named Healthcare Advertising Agency of the Year 2026 by Healthcare Business Review, VUE Health pairs dedicated medical directors on every account with senior strategists and creative leaders who stay hands-on from strategy through launch. Its capabilities span medical strategy, brand and creative, omnichannel media, public relations, market access, and proprietary AI-enabled tools, with deep experience in oncology, rare disease, cardiometabolic, hepatology, and CNS. Learn more at vuehealth.com.

Media contact:

Susan Torres

[email protected]

Sources

- Healthcare Business Review, "VUE Health: The Creative Architects Behind Tomorrow's Breakthrough Medicines"

- https://powerfulbusinesswomen.com/kathryn-wilson-the-art-of-turning-science-into-hope/

SOURCE VUE Health

Share this article

EVANSVILLE, Ind., Oct. 29, 2026 /PRNewswire/ -- Escalade, Inc. (NASDAQ: ESCA, or the "Company"), a leading manufacturer and distributor of sporting goods and indoor/outdoor recreational equipment, today announced results for the third quarter 2026.

THIRD QUARTER 2026 HIGHLIGHTS

(As compared to the third quarter 2025)

- Net sales decreased 3.2% to $65.6 million

- Gross margin improved 123 basis points to 29.4%

- Operating income of $8.7 million compared to $7.3 million

- Net income of $6.7 million, or $0.48 earnings per diluted share, compared to $5.6 million, or $0.40 earnings per diluted share

- EBITDA of $10.0 million compared to $8.6 million

- Pre-tax income includes tariff recoveries of $1.7 million

- Cash provided by operations of $14.9 million compared to cash used of $1.0 million

For the three months ended September 30, 2026, Escalade posted net sales of $65.6 million, net income of $6.7 million and diluted earnings per share of $0.48.

Total net sales decreased 3.2% on a year-over-year basis in the third quarter, primarily driven by lower sales in our basketball, indoor games and table tennis categories against a prior-year period that reflected tariff-related order timing. These decreases were partially offset by increases in our archery category, including strong vertical bow demand and the incremental contribution from our September 2025 acquisition of Gold Tip, as well as increased demand in the safety and outdoor games categories.

Escalade reported third quarter gross margin of 29.4%, an increase of 123 basis points versus the prior-year period, primarily driven by better absorption and a favorable customer and sales mix.

Net income for the third quarter of 2026 was $6.7 million, or $0.48 diluted earnings per share, compared to net income of $5.6 million, or $0.40 diluted earnings per share, for the same quarter in 2025.

Earnings before interest, taxes, depreciation, and amortization ("EBITDA") was $10.0 million in the third quarter of 2026, an increase of $1.4 million versus $8.6 million in the prior-year period. Third quarter 2026 EBITDA included a $1.6 million benefit from the recovery of tariff costs incurred in prior periods.

During the third quarter of 2026, the Company generated $14.9 million in cash flow from operations, compared to cash used of $1.0 million in the prior-year period.

Total debt at the end of the quarter was $13.1 million, down from $20.2 million at the end of the third quarter last year, and $18.5 million at the end of 2025.

Total cash and equivalents as of September 30, 2026 was $24.5 million, while availability on the senior secured revolving credit facility maturing in 2027 was $60.0 million.

Escalade announced a quarterly dividend of $0.1525 per share to be paid to all shareholders of record on January 4, 2027 and payable on January 11, 2027.

MANAGEMENT COMMENTARY

"Our third quarter results demonstrated the resilience of our more efficient operating model, with gross margin expanding 123 basis points year-over-year to 29.4% and strong cash flow from operations," stated Patrick J. Griffin, President and Chief Executive Officer of Escalade. "Consumer demand across our portfolio remained reasonably stable despite deteriorating consumer sentiment. Continued strength in archery, including robust demand for our vertical bows and the incremental contribution from Gold Tip, which we acquired in September 2025, as well as growth in our safety and outdoor games categories drove demand. Reported net sales were unfavorably impacted by comparisons to the third quarter of last year, when tariff-related dynamics shifted the timing of larger customer orders from the second quarter into the third quarter, and by our strategic exit from certain lower-margin product lines."

"Gross margin improvement reflected a favorable sales mix and improved fixed-cost absorption resulting from the acquisitions we completed during 2025, which offset higher freight and material related costs incurred during the quarter," continued Griffin. "Through the first nine months of 2026, we expanded gross margin by more than 210 basis points compared with the same period in 2025. The operational improvements we have made, together with our continued discipline in cost controls and inventory management, have established a margin structure that we believe is sustainable through the cycle."

"As we enter the holiday season, we are working closely with our retail partners to highlight our brands with exciting promotions designed to fuel consumer demand and accelerate sell-through," Griffin added. "We expect inflationary pressures and higher interest rates, as well as broader economic and geopolitical uncertainty, to continue to weigh on consumer spending for discretionary goods. Looking ahead to 2027, we believe our steady cadence of new product launches and a full year of contribution from our recent acquisition will position the business to take market share and generate sales growth, even as consumer headwinds persist."

"Our improved gross margin and strong cash flow enabled us to further strengthen our balance sheet during the third quarter," concluded Griffin. "We continued to prioritize debt repayment, reducing total debt to $13.1 million from $20.2 million a year ago, while increasing cash to $24.5 million and ending the quarter in a net cash position with full availability on our revolving credit facility. Maintaining a strong balance sheet remains a cornerstone of our capital allocation strategy and provides the financial flexibility to pursue acquisitions that broaden and strengthen our business, as demonstrated by our recent acquisition of ASL Solutions. We remain focused on disciplined capital deployment, with the goal of driving profitable growth through the cycle and creating long-term shareholder value."

CONFERENCE CALL

A conference call will be held Thursday, October 29, 2026, at 11:00 a.m. ET to review the Company's financial results, discuss recent events and conduct a question-and-answer session.

A webcast of the conference call and accompanying presentation materials will be available in the Investor Relations section of Escalade's website at www.escaladeinc.com. To listen to a live broadcast, go to the site at least 15 minutes prior to the scheduled start time in order to register, download, and install any necessary audio software.

To participate in the live teleconference:

To listen to a replay of the teleconference, which subsequently will be available through November 12, 2026:

USE OF NON-GAAP FINANCIAL MEASURES

In addition to disclosing financial statements in accordance with U.S. generally accepted accounting principles ("GAAP"), this release contains the non-GAAP financial measure known as "EBITDA." A reconciliation of this non-GAAP financial measure is contained at the end of this press release. EBITDA is a non-GAAP financial measure that Escalade uses to facilitate comparisons of operating performance across periods. Escalade believes the disclosure of EBITDA provides useful information to investors regarding its financial condition and results of operations. Non-GAAP measures should be viewed as a supplement to and not a substitute for the Company's U.S. GAAP measures of performance and the financial results calculated in accordance with U.S. GAAP and reconciliations from these results should be carefully evaluated. Non-GAAP measures have limitations as an analytical tool and should not be considered in isolation or in lieu of an analysis of the Company's results as reported under U.S. GAAP and should be evaluated only on a supplementary basis.

ABOUT ESCALADE

Founded in 1922, and headquartered in Evansville, Indiana, Escalade® designs, manufactures, and sells sporting goods, safety, fitness, pet, and indoor/outdoor recreation equipment. Our mission is to connect family and friends, create lasting memories, and play life to the fullest. Leaders in our respective categories, Escalade's distinct and acclaimed brands include Goalrilla⢠in-ground basketball hoops; STIGA® tennis tables and accessories; Bear Archery® and archery equipment; Brunswick Billiards® tables and accessories; Accudart® darting; ONIX® pickleball; Lifeline® fitness products; and RAVE Sports® water recreation products. Escalade's products are available online and through leading retailers nationwide. For more information about Escalade's diverse and prominent brand portfolio, history, financials, and governance, please visit www.escaladeinc.com.

INVESTOR RELATIONS CONTACT

Wesley Smith

Vice President, Financial Reporting & Investor Relations

812-467-1334

FORWARD-LOOKING STATEMENTS

This report contains statements that we believe are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Rule 175 promulgated thereunder, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and Rule 3b-6 promulgated thereunder. All statements, other than statements of historical fact, are forward-looking statements. These statements relate to our financial condition, results of operations, plans, objectives, future performance, capital actions or business. They usually can be identified by the use of forward-looking language such as "will likely result," "may," "are expected to," "is anticipated," "potential," "estimate," "forecast," "projected," "intends to," or may include other similar words or phrases such as "believes," "plans," "trend," "objective," "continue," "remain," or similar expressions, or future or conditional verbs such as "will," "would," "should," "could," "might," "can," or similar verbs. You should not place undue reliance on these statements, as they are subject to risks and uncertainties.